接种阿斯利康（AZD1222）COVID-19 疫苗后免疫介导的坏死性肌病：病例报告及简要回顾。
Immune-mediated necrotizing myopathy following vaccination with the AstraZeneca (AZD1222) COVID-19 vaccine: A case report and brief review.
机构信息
Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Rothman Orthopedics, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
出版信息
Rev Neurol (Paris). 2023 Jun;179(6):630-635. doi: 10.1016/j.neurol.2022.11.009. Epub 2023 Feb 1.
Immune-Mediated Necrotizing Myopathy (IMNM) after vaccination has been reported previously, however it is rare after COVID-19 vaccination. We report the first case of IMNM two weeks after vaccination with the AstraZeneca (AZD1222) COVID-19 vaccine. There was a probable temporal relationship between the COVID-19 vaccination and the development of IMNM due to lack of known causative factors for IMNM. This may have been due to 1) autoimmunity directly caused by the vaccine, 2) exacerbation of autoimmunity triggered by the vaccine or 3) autoimmune syndrome triggered by the vaccine adjutants. Further studies are needed to assess the underlying mechanisms.
免疫介导性坏死性肌病（IMNM）在接种疫苗后已有报道，但在 COVID-19 疫苗接种后很少见。我们报告了首例接种阿斯利康（AZD1222）COVID-19 疫苗后两周发生的 IMNM 病例。由于缺乏 IMNM 的已知病因，COVID-19 疫苗接种与 IMNM 的发生之间可能存在时间上的关系。这可能是由于 1）疫苗直接引起的自身免疫，2）疫苗引发的自身免疫加剧，或 3）疫苗佐剂引发的自身免疫综合征。需要进一步研究来评估潜在的机制。
Zotero 插件